The study assessed the use of the interleukin-23 inhibitor icotrokinra (Protagonist Therapeutics, Johnson & Johnson) in adult and adolescent patients with moderate-to-severe plaque psoriasis.

If you have psoriasis, a chronic condition that primarily affects the skin, you might not know that it can also affect your eyes. But the inflammation that causes lesions on your skin is systemic ...

Psoriasis can be alarming if you’re newly diagnosed. When you look at your patch (or patches) of thick, red skin, you probably want to know two things: How can I make this disappear? And how can ...

The FDA slapped a clinical hold on a phase 1b plaque psoriasis trial after testicular toxicity was reported in dogs from a nonclinical test. Research into the use of BET inhibitors to treat cancer ...

Psoriasis has many imitators, but one that comes very close is seborrheic dermatitis. That’s because both conditions can cause red, scaly, inflamed patches on your skin. To tell the two apart ...

The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. Led by AbbVie’s Humira, biologic TNF ...

A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity ...

A RECENT clinical trial has compared the effectiveness of IL-17 and IL-23 biologics in treating moderate to severe plaque psoriasis, particularly in patients with coexisting metabolic syndrome (MetS).

Patanjali Ayurved has achieved another milestone that could lead to a major breakthrough in the treatment of 'psoriasis', a severe skin ailment. The company said that its research on this disease has ...

Patanjali Ayurved's research, published in the Journal of Inflammation Research, reveals promising results for their Ayurvedic treatment of psoriasis using Psorogrit tablets and Divya Taila.